Professor Michael Murray

Professor
Pharmacology, School of Medical Sciences

Telephone +61 2 9351 2326; MFB +61 2 9036 3259
Fax +61 2 9351 6950; MFB +61 2 9351 4447

Map

Biographical details

Michael Murray graduated with a Bachelor of Pharmacy with First Class Honours and a PhD in Pharmaceutical Chemistry from the University of Sydney. After undertaking postdoctoral research with CF Wilkinson in the Institute for Comparative and Environmental Toxicology at Cornell University, Ithaca, NY he returned to Westmead Hospital and was appointed as an HMRC Research Fellow in 1987, promoted to NHMRC Senior Research Fellow in 1989 and to NHMRC Principal Research Fellow in 1994. In 1995 he received a DSc from The University of Sydney.

After 5 years at UNSW in The School of Physiology and Pharmacology, he returned in July, 2003 to the University of Sydney's Faculty of Pharmacy to take up the inaugural Chair of Pharmacogenomics. The Pharmacogenomics and Drug Development research laboratory is located in the Faculty's new laboratories in the Medical Foundation Building. Michael Murray is the author of 142 original papers and 27 review articles since 1982 and has presented 70 invited seminars, workshops and symposia in Australia, North America, Singapore and the United Kingdom. He was the 2002 ASCEPT visitor to the British Toxicology Society. He has been associated with the International Society for the Study of Xenobiotics (as Councillor 1986-1989), the Australasian Society for Clinical and Experimental Pharmacologists and Toxicologists (Councillor and convenor of the Drug Metabolism, Delivery and Pharmacokinetics section 2000-2003 and Deputy Chair of the Scientific Advisory Committee 2002-present) and the Gastroenterological Society of Australia (Research Advisory Committee 1989-1995). He currently serves on the editorial boards of Toxicology and Applied Pharmacology, Xenobiotica and Current Drug Metabolism and was a recent member of the editorial board of the Journal of Gastroenterology and Hepatology.

Research interests

  • Human drug metabolism
  • Cytochrome P450 (CYP) pharmacogenetics
  • CYP regulation by drugs, nutrients and endobiotics
  • Adverse drug reactions caused by reactive drug metabolites
  • Drug-drug interactions due to inhibition of P450 enzymes

Selected grants

2014

  • CLARIOstar Multifunctional Microplate Reader for Shared Used at the Open Access, Multi-User Molecular Biology Core Facility; Huang M, Scolyer R, Fraser S, Sahni S, Speranza T, Owens T, Barrs V, Ju Y, Kovacevic Z, Lu Z, Camp A, Slobedman B, Morris B, Oliver B, Dos Remedios C, Kalinowski D, Fu D, Lai D, Lovicu F, Allbutt H, Triccas J, Burgess J, Kril J, Dixon K, Rendina L, Byrne M, King N, Groundwater P, Williamson P, Ho J, Dong Q, Bao B, Assinder S, McLennan S, Richardson D, Ammit A, Sharland A, Hardikar A, Hong A, Hambly B, Lee C, Murphy C, Goldsbury C, Johnstone D, Lane D, Hibbs D, Joshua D, Huq F, Halliday G, Sutherland G, Zreiqat H, Lok H, Lyons G, Jansson P, Black J, Zhu L, Sunde M, Day M, Naylor M, Buckland M, Murray M, Shafie N, Lay P, Poronnik P, Codd R, Mason R, Ryan R, Christopherson R, de Graaf S; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2013

  • BioMark HD High-throughput Real Time & Digital PCR System for the Open Access, Multi-Disciplinary Sydney Cancer Research Core Facility; Richardson D, Scolyer R, Lee C, Halliday G, Murray M, Lay P, Christie M, Kench J, Damian D, Hersey P; Cancer Institute New South Wales/Equipment Grant.
  • Robotic High Throughput Western Analysis for the Open Access, Multi-User Sydney Cancer Research Core Facility; Richardson D, Scolyer R, Boyer M, Halliday G, Damian D, Christopherson R, Joshua D, Kench J, Hong A, Murray M, Lee C, Kalinowski D, Naylor M, Lay P, Lyons G, Kovacevic Z, Mason R, Dixon K, Chan-Ling T, Hawkins C, Sunde M, Lovejoy D, Owens T, Rendina L, Jansson P, Dos Remedios C, Charles (nee Slaviero) K, Lane D, Witting P, Dong Q, Ammit A, Groundwater P, Assinder S, Bao B, Byrne S, Zhou F, Buckland M, Grewal T, Huq F, Lai D, Codd R, Zhang D, Fu D, de Graaf S, Huang M, Payne R, Slobedman B, Barrs V, Ho J, Williamson P, Murphy C; DVC Research/Equipment Grant.
  • QX100 Droplet Digital PCR system for Shared Used at the Open Access, Multi-User Molecular Biology Core Facility; Richardson D, Kril J, Murphy C, Vandenberg R, Rendina L, Dos Remedios C, Ju Y, Kovacevic Z, Lyons G, Sutherland G, Lay P, Ammit A, Lai D, Morris B, Day M, Dong Q, Bao B, Huang M, Camp A, Boyer M, Whittington R, Byrne M, Hanrahan J, Fu D, Jansson P, Lane D, Bagley E, Hibbs D, Zhang D, Fraser S, Scolyer R, Black J, Halliday G, Christie M, Zreiqat H, Murray M, Slobedman B, Naylor M, Burgess J, Triccas J, Mason R, Chadban S, Combes V, Lovicu F, McLennan S, Kalinowski D, Sharland A, Johnstone D, Groundwater P, Dixon K, Zhou F, Lovejoy D, Lu Z, Zhu L, Goldsbury C, Witting P, Buckland M, Assinder S, Purdie (Williams) A, Codd R, Owens T, Hambly B; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • WITEC Alpha 300R High Throughput Microscope - Confocal Raman Microscope; Traini D, Young P, Murray M, Dehghani F, Chan K, Oliver B, Holst J; DVC Research/Equipment Grant.
  • Over-expression of human cytochrome P450 2J2 activates phase II biotransformation genes that influence anti-cancer drug efficacy; Murray M, Mackenzie P; National Health and Medical Research Council (NHMRC)/Project Grants.
  • A randomised study to optimise clinical outcomes in patients with FLT3 mutant AML; Wei A, Bradstock K, Levis M, Murray M, Roberts A; National Health and Medical Research Council (NHMRC)/Project Grants.

2012

  • Novel cellular trafficking mechanisms for the drug influx transporter, human Organic Anion Transporting Polypeptide 1a2 (Oatp1a2); Zhou F, Murray M; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Pharmacological development of synthetic analogues of cytochrome P450-mediated omega-3 fatty acid epoxides as novel anti-metastatic agents; Murray M, Duke C, Cui P, Ching L, Dunstan C; National Health and Medical Research Council (NHMRC)/Project Grants.
  • GeneAtlas Personal Microarray System; Richardson D, Scolyer R, Stocker R, Weninger W, Black J, Allen D, Murray M, Mason R, Twigg S, King N, Horvath L, Lovicu F, Lee C, Halliday G, Lovejoy D, Joshua D, Sharland A, Roufogalis B, Hambly B, Morris B, Bao B, Bishop A, Hibbs D, Lane D, Zhou F, Hanrahan J, Dixon K, Rendina L, Byrne M, Naylor M, Cole N, Jansson P, Dong Q, Codd R, Payne R, Assinder S, Chadban S, Fraser S, McLennan S, Suryo Rahmanto A, Lai D, Yu Y, Ju Y, Buckland M, Kovacevic Z, Saletta F, Zreiqat H, Kalinowski D, Groundwater P, Simes R, Zhang D, Boyer M, Murphy C; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2011

  • Leucine Zipper factors regulate the Human CYP2J2 gene; Murray M; DVC Research/Bridging Support Grant.
  • PyroMark Q96 ID system; Richardson D, Stone J, Black J, King N, Mason R, Hunt N, Kril J, Murray M, Scolyer R, Halliday G, Vandenberg R, McMinn P, Chadban S, Byrne M, Ryan R, Dong Q, Lee C, Bishop A, Haass N, Fraser S, Hambly B, Sharland A, Kalinowski D, Assinder S, Yu Y, Bao B, Ju Y, Lovejoy D, Buckland M, Lane D, Dos Remedios C, Kovacevic Z, Sutherland G, Zhang D, Morris B, Suryo Rahmanto A, Murphy C; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • PHARMACOGENOMIC APPROACHES TO MINIMISE SORAFENIB TOXICITY IN PATIENTS WITH LIVER CANCER; Murray M; Cancer Council New South Wales/Innovator Grant.

2010

  • GenomeLab GeXP Genetic Analysis System for the Multi-Disciplinary Sydney Cancer Gene Expression Facility; Richardson D, Halliday G, Scolyer R, Clarke S, Lee C, Reichardt J, Clarke C, Murray M, Boyer M, Kefford R; Cancer Institute New South Wales/Equipment Grant.
  • Functional interplay of transcriptional activators in the regulation of the cytoprotective human CYP2J2 gene; Murray M; DVC Research/Bridging Support Grant.

2009

  • Organic anion transporting polypeptide 1A2 pharmocogenetcs in the determination of personalized treatment protocols with imatinib; Zhou F, Murray M, McLachlan A; Pharmacy Research Trust of NSW/Research Support.
  • PSIA Thermal Atomic Force Microscope (AFM), XE-70 SPM system plus Scanning Thermal Microscope; Murray M, Chan K, Traini D; Clive & Vera Ramaciotti Foundation/Awards for Biomedical Research: Major Equipment.
  • Bruker APEX II CCD Detector Fourth Generation APEX II ultra-low noise CCD X-ray detector with 16 megapixel chip; Hibbs D, Roufogalis B, Murray M, Hambley T, Hanrahan J, Church W, Collins M, Johnston G, Young P, Traini D; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Development of personalised dosage protocols for tyrosine kinase inhibitors in oncology patients; Murray M, Gurney H, McLachlan A; Cancer Council New South Wales/Research Project Grants.
  • Cytochrome P450-mediated epoxides of polyunsaturated fatty acids that regulate cell death and survival; Murray M; National Health and Medical Research Council (NHMRC)/Project Grants.

2008

  • Varian NMR System 400MHz & Autosampler; Murray M; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2007

  • Functional interplay of transcriptional activators in the regulation of the cytoprotective human; Murray M; National Health and Medical Research Council (NHMRC)/Project Grants.
  • State of the art high resolution thermal analysis suite for the life and material sciences; Stewart P, Young P, Traini D, Chan K, Murray M, Dehghani F, Hibbs D, Larson I, Warr G, Weiss A; Australian Research Council (ARC)/Linkage Infrastructure, Equipment and Facilities (LIEF).
  • Precision Titration/ Solution Calorimeter accessory for the Tam III Iosthermal calorimeter Calorimet; Chan K, Murray M, Hibbs D, Young P, Traini D, Weiss A, Stewart P; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2006

  • Epoxygenase-derived eicosanoids as endogenous anti-inflammatory and hypoxia-reperfusion protective agents in vasculature; Petrovic N, Murray M; University of Sydney/Research & Development.
  • Novel omega-3 fatty acid epoxides and the activation of cellular pathways; Murray M; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Advanced Imaging Flow Cytometry Facility for NSW; King N, Campbell I, Cook D, Black J, Halliday G, McAvoy J, Gunning P, Pollard J, Murray M, Britton W, Dawes I, Khachigian L, Hunt N; Australian Research Council (ARC)/Linkage Infrastructure, Equipment and Facilities (LIEF).

2005

  • Stimulation of mitogenic signalling and cell survival by w-3 fatty acid epoxides; Murray M; University of Sydney/Research & Development.
  • 7500 Real-time PCR instrument plus software; Roufogalis B, Armour C, Collins M, Ammit A, Murray M, Hughes M; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2004

  • Clozapine toxicity:role of pharmacogenetic variation in CYP enzymes and bioactivation mechanisms in patient neutrophils; Murray M, Velakoulis D; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Alternate signalling pathways regulating the human arachidonate epoxygenase CYP2J2 in response to stress stimuli; Murray M, Robertson G; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Impact of human cytochrome P450 3A allelic variants on the toxicity of docetaxel and irinotecan; Clarke S, Ramzan I, Murray M; University of Sydney/Cancer Research Fund.

2001

  • Regulations of cytochrome P450 turnover in experimental hepatic steatosis; Murray M; National Health and Medical Research Council (NHMRC)/Project Grants.

2000

  • Vitamin A & the dietary modulation of drug metabolising enzymes (1994); Murray M; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Ghassabian, S., Murray, M. (2013). Simultaneous In Vivo Phenotyping of CYP Enzymes. In Phillips, Ian R.; Shephard, Elizabeth A.; Ortiz de Montellano, Paul R (Eds.), Cytochrome P450 Protocols, (pp. 261-267). New York: Springer.
  • Armour, C., Chaar, B., Murray, M., Ambler, G., Krass, I. (2012). Current therapies and pharmacy programs for obesity and diabetes. In Louise A. Baur, Stephen M. Twigg, Roger S.Magnusson (Eds.), A Modern Epidemic: Expert Perspectives on Obesity and Diabetes, (pp. 315-338). Sydney, Australia: Sydney University Press.
  • Murray, M. (2012). Introduction and Overview. In Pavel Anzenbacher and Ulrich M Zanger (Eds.), Metabolism of Drugs and Other Xenobiotics, (pp. 519-542). Weinheim: Wiley - V C H Verlag GmbH & Co. KGaA.
  • Petrovic, N., Murray, M. (2010). Using N,N,N',N'-tetramethyl-p-phenylenediamine (TMPD) to assay cyclooxygenase activity in vitro. In Donald Armstrong (Eds.), Methods in Molecular Biology: Advanced Protocols in Oxidative Stress II, (pp. 129-140). New York USA: Humana Press.
  • Murray, M. (2008). Modulation of Cytochromes P450 by Phytochemicals. In Costas Ioannides (Eds.), Cytochromes P450: Role in the Metabolism and Toxicity of Drugs and other Xenobiotics, (pp. 449-479). UK: RSC Publishing.
  • Petrovic, N., Murray, M. (2008). Modulation of Tumor Angiogenesis by Polyunsaturated Fatty Acids: What is the Mechanism? In Peter B. Murphy and Jason R. Clarke (Eds.), Oncogene Proteins: Structure, Functions and Analyses, (pp. 117-138). USA: Nova Science Publishers.
  • Shankar, G., Charleston, M., Murray, M., Hibbs, D. (2007). A structural and phylogenetic analysis of cytochrome P450. In Damjana Rozman (Eds.), Proceedings of the 15th International Conference on Cytochromes P450: Biochemistry, Biophysics and Functional Genomics, (pp. 75-80). Bologna, Italy: Medimond.

Journals

  • Toh, D., Limenta, L., Yee, J., Wang, L., Goh, B., Murray, M., Lee, E. (2014). Effect of mushroom diet on pharmacokinetics of gabapentin in healthy Chinese subjects. British Journal of Clinical Pharmacology, 78(1), 129-134. [More Information]
  • Murray, M., Dyari, H., Allison, S., Rawling, T. (2014). Lipid analogues as potential drugs for the regulation of mitochondrial cell death. British Journal of Pharmacology, 171(8), 2051-2066. [More Information]
  • Murray, M. (2014). ω-3 polyunsaturated fatty acids and their metabolites as inhibitors of mammalian tumorigenesis. Phytochemistry Reviews, 13(1), 139-156. [More Information]
  • Cui, P., Rawling, T., Gillani, T., Bourget, K., Wang, X., Zhou, F., Murray, M. (2013). Anti-proliferative actions of N'-desmethylsorafenib in human breast cancer cells. Biochemical Pharmacology, 86(3), 419-427. [More Information]
  • Zhou, F., Zheng, J., Zhu, L., Jodal, A., Cui, P., Wong, K., Gurney, H., Church, W., Murray, M. (2013). Functional Analysis of Novel Polymorphisms in the Human SLCO1A2 Gene that Encodes the Transporter OATP1A2. The AAPS Journal, 15(4), 1099-1108. [More Information]
  • Toh, D., Cheung, F., Murray, M., Pern, T., Lee, E., Zhou, F. (2013). Functional Analysis of Novel Variants in the Organic Cation/Ergothioneine Transporter 1 Identified in Singapore Populations. Molecular Pharmaceutics, 10(7), 2509-2516. [More Information]
  • Cui, P., Rawling, T., Bourget, K., Kim, T., Duke, C., Doddareddy, M., Hibbs, D., Zhou, F., Tattam, B., Petrovic, N., Murray, M. (2012). Antiproliferative and Antimigratory Actions of Synthetic Long Chain n-3 Monounsaturated Fatty Acids in Breast Cancer Cells That Overexpress Cyclooxygenase-2. Journal of Medicinal Chemistry, 55(16), 7163-7172. [More Information]
  • Ghassabian, S., Rawling, T., Zhou, F., Doddareddy, M., Tattam, B., Hibbs, D., Edwards, R., Cui, P., Murray, M. (2012). Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites. Biochemical Pharmacology, 84(2), 215-223. [More Information]
  • Rawling, T., McDonagh, A., Tattam, B., Murray, M. (2012). Synthesis of unsymmetrical biaryl ureas from N-carbamoylimidazoles: kinetics and application. Tetrahedron, 68(30), 6065-6070. [More Information]
  • Murray, M. (2012). Toxicological actions of plant-derived and anthropogenic methylenedioxyphenyl-substituted chemicals in mammals and insects. Journal of Toxicology and Environmental Health. Part B: Critical Reviews, 15(6), 365-395. [More Information]
  • Toh, S., Murray, M., Tan, K., Mulay, V., Grewal, T., Lee, E., Zhou, F. (2011). Functional analysis of pharmacogenetic variants of human organic cation/carnitine transporter 2 (hOCTN2) identified in Singaporean populations. Biochemical Pharmacology, 82(11), 1692-1699. [More Information]
  • Zhou, F., Lee, A., Krafczyk, K., Zhu, L., Murray, M. (2011). Protein Kinase C Regulates the Internalization and Function of the Human Organic Anion Transporting Polypeptide 1A2. British Journal of Pharmacology, 162(6), 1380-1388. [More Information]
  • Cui, P., Petrovic, N., Murray, M. (2011). The ω-3 Epoxide of Eicosapentaenoic Acid Inhibits Endothelial Cell Proliferation by p38 MAP Kinase Activation and Cyclin D1/CDK4 Down-Regulation. British Journal of Pharmacology, 162(5), 1143-1155. [More Information]
  • Rong, X., Li, Y., Ebihara, K., Zhao, M., Naowaboot, J., Kusakabe, T., Kuwahara, K., Murray, M., Nakao, K. (2010). Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice. Diabetologia: clinical and experimental diabetes and metabolism, 53, 1727-1731. [More Information]
  • Murray, M. (2010). Cytochromes P450: Roles in the Biotransformation of Chemicals in Cigarette Smoke and Impact of Smoking Cessation on Concurrent Drug Therapy. Journal of Smoking Cessation, 5(2), 107-114. [More Information]
  • Rawling, T., Duke, C., Cui, P., Murray, M. (2010). Facile and Stereoselective Synthesis of (Z)-15-Octadecenoic Acid and (Z)-16-Nonadecenoic Acid: Monounsaturated Omega-3 Fatty Acids. Lipids, 45(2), 159-165. [More Information]
  • Zhou, F., Zhu, L., Cui, P., Church, W., Murray, M. (2010). Functional characterization of nonsynonymous single nucleotide polymorphisms in the human organic anion transporter 4 (hOAT4). British Journal of Pharmacology, 159, 419-427. [More Information]
  • Toh, S., Yee, J., Koo, S., Murray, M., Lee, E. (2010). Genetic Variations of the SLC22A5 Gene in the Chinese and Indian Populations of Singapore. Drug Metabolism and Pharmacokinetics, 25(1), 112-119. [More Information]
  • D'Esposito, F., Nebot, N., Edwards, R., Murray, M. (2010). Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease. British Journal of Clinical Pharmacology, 70(3), 400-408. [More Information]
  • Cui, P., Lee, A., Zhou, F., Murray, M. (2010). Impaired transactivation of the human CYP2J2 arachidonic acid epoxygenase gene in HepG2 cells subjected to nitrative stress. British Journal of Pharmacology, 159(7), 1440-1449. [More Information]
  • Rong, X., Li, Y., Ebihara, K., Zhao, M., Kusakabe, T., Tomita, T., Murray, M., Nakao, K. (2010). Irbesartan treatment up-regulates hepatic expression of PPARalpha and its target genes in obese Koletsky (fa(k)/fa(k)) rats: a link to amelioration of hypertriglyceridaemia. British Journal of Pharmacology, 160(7), 1796-1807. [More Information]
  • Nebot, N., Crettol, S., D'Esposito, F., Tattam, B., Hibbs, D., Murray, M. (2010). Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. British Journal of Pharmacology, 161(5), 1059-1069. [More Information]
  • Crettol, S., Petrovic, N., Murray, M. (2010). Pharmacogenetics of phase I and phase II drug metabolism. Current Pharmaceutical Design, 16(2), 204-219. [More Information]
  • Murray, M., Cui, P., Zhou, F. (2010). Roles of Mitogen-Activated Protein Kinases in the Regulation of CYP Genes. Current Drug Metabolism, 11(10), 850-858. [More Information]
  • Ghassabian, S., Chetty, M., Tattam, B., Glen, J., Rahme, J., Stankovic, Z., Ramzan, I., Murray, M., McLachlan, A. (2010). The participation of cytochrome P450 3A4 in clozapine biotransformation is detected in people with schizophrenia by high-throughput in vivo phenotyping. Journal of Clinical Psychopharmacology, 30(5), 629-631. [More Information]
  • Lee, A., Murray, M. (2010). Up-Regulation of Human CYP2J2 in HepG2 Cells by Butylated Hydroxyanisole Is Mediated by c-Jun and Nrf2. Molecular Pharmacology, 77(6), 987-994. [More Information]
  • Li, Y., Saito, Y., Kuwahara, K., Rong, X., Kishimoto, I., Harada, M., Horiuchi, M., Murray, M., Nakao, K. (2010). Vasodilator therapy with hydralazine induces angiotensin AT2 receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A. British Journal of Pharmacology, 159, 1133-1142. [More Information]
  • Ghassabian, S., Chetty, M., Tattam, B., Glen, J., Rahme, J., Stankovic, Z., Ramzan, I., Murray, M., McLachlan, A. (2009). A high-throughput assay using liquid chromatography-tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome p450 enzymes in patients. Therapeutic Drug Monitoring, 31(2), 239-246. [More Information]
  • Rong, X., Li, Y., Ebihara, K., Zhao, M., Aini, W., Kusakabe, T., Hirata, M., Miyamoto, L., Murray, M., Nakao, K. (2009). An Adipose Tissue-Independent Insulin-Sensitizing Action of Telmisartan: a Study in Lipodystrophic Mice. Journal of Pharmacology and Experimental Therapeutics, 331(3), 1096-1103. [More Information]
  • Toh, S., Koo, S., Limenta, L., Yee, J., Murray, M., Lee, E. (2009). Genetic Variations of the SLC22A4 Gene in Chinese and Indian Populations of Singapore. Drug Metabolism and Pharmacokinetics, 24(5), 475-481.
  • Li, Y., Saito, Y., Kuwahara, K., Rong, X., Kishimoto, I., Harada, M., Adachi, Y., Nakanishi, M., Kinoshita, H., Horiuchi, M., Murray, M., et al (2009). Guanylyl Cyclase-A Inhibits Angiotensin II Type 2 Receptor-Mediated Pro-Hypertrophic Signaling in the Heart. Endocrinology, 150(8), 3759-3765. [More Information]
  • Chetty, M., D'Esposito, F., Zhang, W., Glen, J., Dore, G., Stankovic, Z., Edwards, R., Ramzan, I., Murray, M. (2009). In vitro and in vivo evaluation of the inhibition potential of risperidone toward clozapine biotransformation. British Journal of Clinical Pharmacology, 68(4), 574-579. [More Information]
  • Xu, H., Murray, M., McLachlan, A. (2009). Influence of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Sulfonylurea Drugs. Current Drug Metabolism, 10(6), 643-658. [More Information]
  • Cui, P., Zhang, W., Hook, J., Tattam, B., Duke, C., Murray, M. (2009). Synthesis and NMR characterization of the methyl esters of eicosapentaenoic acid monoepoxides. Chemistry and Physics of Lipids, 159(1), 30-37. [More Information]
  • Millar, A., Qi, Y., Rong, X., Jiang, J., Yang, Q., Yamahara, J., Murray, M., Li, Y. (2009). The Ayurvedic medicine Salacia oblonga attenuates diabetic renal fibrosis in rats: suppression of angiotensin II/AT1 signaling. Evidence-Based Complementary and Alternative Medicine, , 1 of 13-13 of 13. [More Information]
  • D'Esposito, F., Tattam, B., Ramzan, I., Murray, M. (2008). A liquid chromatography/electrospray ionization mass spectrometry (LC-MS/MS) assay for the determination of irinotecan (CPT-11) and its two major metabolites in human liver microsomal incubations and human plasma samples. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 875(2), 522-530. [More Information]
  • Rong, X., Kim, M., Su, N., Wen, S., Matsuo, Y., Yamahara, J., Murray, M., Li, Y. (2008). An aqueous extract of Salacia oblonga root, a herb-derived peroxisome proliferator-activated receptor-alpha activator, by oral gavage over 28 days induces gender-dependent hepatic hypertrophy in rats. Food and Chemical Toxicology, 46(6), 2165-2172. [More Information]
  • Xu, H., Williams, K., Liauw, W., Murray, M., Day, R., McLachlan, A. (2008). Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. British Journal of Pharmacology, 153(7), 1579-1586. [More Information]
  • Li, Y., Qi, Y., Kim, M., Zhe-Yang Xu, K., Huang, H., Rong, X., Murray, M., Yamahara, J. (2008). Increased renal collagen cross-linking and lipid accumulation in nephropathy of Zucker diabetic fatty rats. Diabetes - Metabolism: Research and Reviews, 24(6), 498-506. [More Information]
  • Zhang, W., D'Esposito, F., Edwards, R., Ramzan, I., Murray, M. (2008). Interindividual Variation in Relative CYP1A2/3A4 Phenotype Influences Susceptibility of Clozapine Oxidation to Cytochrome P450-Specific Inhibition in Human Hepatic Microsomes. Drug Metabolism and Disposition, 36(12), 2547-2555. [More Information]
  • Szymczak, M., Murray, M., Petrovic, N. (2008). Modulation of angiogenesis by omega-3 polyunsaturated fatty acids is mediated by cyclooxygenases. Blood, 111(7), 3514-3521. [More Information]
  • Chetty, M., Murray, M. (2007). CYP-mediated clozapine interactions: how predictable are they? Current Drug Metabolism, 8(4), 307-313. [More Information]
  • Zhang, W., Ramzan, I., Murray, M. (2007). Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis. Journal of Pharmacology and Experimental Therapeutics, 322(2), 770-777. [More Information]
  • Fiala-Beer, E., Lee, A., Murray, M. (2007). Regulation of the rat CYP4A2 gene promoter by c-Jun and octamer binding protein-1. The International Journal of Biochemistry and Cell Biology, 39(6), 1235-1247. [More Information]
  • Murray, M. (2007). Role of signalling systems in the effects of dietary factors on the expression of mammalian CYPs. Expert Opinion on Drug Metabolism and Toxicology, 3(2), 185-196. [More Information]
  • Murray, M. (2006). Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis. Current Drug Metabolism, 7(1), 67-81. [More Information]
  • Murray, M., Petrovic, N. (2006). Cytochromes P450: Decision-making tools for personalized therapeutics. Current Opinion in Molecular Therapeutics, 8(6), 480-486. [More Information]
  • Obligacion, R., Murray, M., Ramzan, I. (2006). Drug-Metabolizing Enzymes and Review Transporters: Expression in the Human Prostate and Roles in Prostate Drug Disposition. Journal Of Andrology, 27(2), 138-150. [More Information]
  • Cowpland, C., Quee, G., Murray, M., Puddey, I., Croft, K. (2006). Effect of alcohol on cytochrome P450 arachidonic acid metabolism and blood pressure in rats and its modulation by red wine polyphenolics. Clinical and Experimental Pharmacology and Physiology, 33(3), 183-188. [More Information]
  • Murray, M. (2006). Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. Journal of Pharmacy and Pharmacology, 58(7), 871-885. [More Information]
  • Marden, N., Murray, M. (2005). Characterization of a c-Jun-responsive module in the 5'-flank of the human CYP2J2 gene that regulates transactivation. Biochemical Journal, 391(3), 631-640. [More Information]
  • Murray, M., Butler, A., Fiala-Beer, E., Su, G. (2005). Phospho-STAT5 accumulation in nuclear fractions from vitamin A-deficient rat liver. FEBS Letters, 579(17), 3669-3673. [More Information]
  • Su, G., Fiala-Beer, E., Weber, J., Jahn, D., Robertson, G., Murray, M. (2005). Pretranslational upregulation of microsomal CYP4A in rat liver by intake of a high-sucrose, lipid-devoid diet containing orotic acid. Biochemical Pharmacology, 69(4), 709-717. [More Information]
  • Liu, L., Murray, M., Conlon, J., Burcher, E. (2005). Quantitative Structure-Activity analyses of bufokinin and other tachykinins at bufokinin (bNK1) receptors of the small intestine of the can toad, Bufo marinus. Biochemical Pharmacology, 69(2), 329-338. [More Information]
  • Murray, M., Butler, A. (2004). Comparative Inhibition Of Inducible And Constitutive Cyps In Rat Hepatic Microsomes By Parathion. Xenobiotica, 34(8), 723-739.
  • Liu, L., Markus, I., Vandenberg, R., Neilan, B., Murray, M., Burcher, E. (2004). Molecular Identification And Characterization Of Three Isoforms Of Tachykinin Nk(1)-Like Receptors In The Cane Toad Bufo Marinus. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology (Print), 287(3), R575-R585.
  • Murray, M., Murray, K. (2003). Mechanism-based inhibition of CYP activities in rat liver by fluoxetine and structurally similar alkylamines. Xenobiotica, 33(10), 973-987.
  • Murray, M. (2003). Pharmacogenetic variation in drug oxidizing CYPs: impact on drug therapy, drug safety and drug interactions. Current Pharmacogenomics and Personalized Medicine, 1(3), 159-173.
  • Marden, N., Fiala-Beer, E., XIANG, S., Murray, M. (2003). Role of activator protein-1 in the down-regulation of the human CYP2J2 gene in hypoxia. Biochemical Journal, 373(3), 669-680.
  • Murray, M., Fiala-Beer, E., Sutton, D. (2003). Upregulation of cytochromes P450 2B in rat liver by orphenadrine. British Journal of Pharmacology, 139(4), 787-796.
  • Stupans, I., Tan, H., Kirlich, A., Tuck, K., Hayball, P., Murray, M. (2002). Inhibition of CYP3A-mediated oxidation in human hepatic microsomes by the dietary derived complex phenol, gallic acid. Journal of Pharmacy and Pharmacology, 54, 269-275.
  • Liu, L., Murray, M., Burcher, E. (2002). Structure-activity studies of bufokinin, substance P and their C-terminal fragments at bufokinin receptors in the small intestine of the cane toad, Bufo marinus. Biochemical Pharmacology, 63(2), 217-224.
  • Hoskins, J., Shenfield, G., Murray, M., Gross, A. (2001). Characterization of moclobemide N-oxidation in human liver microsomes. Xenobiotica, 31(7), 387-397.
  • Murray, M., Sefton, R., Croft, K., Butler, A. (2001). Differential regulation of endobiotic-oxidizing cytochromes P450 in vitamin A-deficient male rat liver. British Journal of Pharmacology, 134(7), 1487-1497.
  • Stupans, I., Murray, M., Kirlich, A., Tuck, K., Hayball, P. (2001). Inactivation of cytochrome P450 by the food-derived complex phenol oleuropein. Food and Chemical Toxicology, 39, 1119-1124.

Conferences

  • Murray, M., Zhang, W., Duke, C., Ramzan, I. (2006). Accumulation of esterified polyunsaturated fatty acids in hepatic steatosis impairs microsomal clozapine oxidation. Australian Health and Medical Research Congress, Melbourne: Australian Health and Medical Research Congress.
  • Murray, M., Marden, N., Lee, A. (2006). Altered CYP expression and function by dietary factors: Potential roles in disease pathogenesis. 14th North American ISSX (International Society for the Study of Xenobiotics) Meeting, United States: Informa Healthcare.
  • D'Esposito, F., Tattam, B., Ramzan, I., Murray, M. (2006). Development of a high throughput LC/MS/MS method for the determination of the anticancer agent irinotecan and its two major metabolites. Australian Health and Medical Research Congress, Melbourne: Australian Health and Medical Research Congress.
  • Murray, M., Zhang, W., Ramzan, I. (2006). Hepatic lipid accumulation in experimental steatosis influences microsomal clozapine oxidation capacity.
  • Murray, M., Zhang, W., Ramzan, I. (2006). Hepatic lipid accumulation in experimental steatosis influences microsomal clozapine oxidation capacity. 14th North American ISSX (International Society for the Study of Xenobiotics) Meeting, United States: Informa Healthcare.
  • Shankar, G., Charleston, M., Murray, M., Hibbs, D. (2006). Phylogenetic analysis of cytochrome P450 structures. BIOINFORMATICS AUSTRALIA 2006, Sydney: NSW Office for Science and Medical Research.
  • Lee, A., Marden, N., Murray, M. (2005). Potential transcriptional control elements in the 5'-upstream region of the human CYP2J2 gene. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Conference. World Scientific Publishing.
  • Murray, M., Fiala-Beer, E. (2005). Role of c-Jun in the transcriptional activation of the rat cytochrome P450 (CYP) 4A2. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Conference. World Scientific Publishing.
  • Ghassabian, S., Murray, M., Chetty, M., Glen, J. (2005). The impact of Valproate on Plasma Concentrations of Clozapine nad Its Major Metabolites in Patients with Schizophrenia. Joint Meeting of Ascept and Apsa, Melbourne: Australian Society of Clinical and experimental Pharmacologists and Toxicologista.
  • Marden, N., Murray, M. (2004). Characterisation of a c-jun-responsive module in the 5'-flank of the human CYP2J2 gene that regulates expression. Australian Health and Medical Research Congress, Melbourne: Australian Health and Medical Research Congress.
  • Murray, M., Fiala-Beer, E., Weber, J., Robertson, C., Farrell, G., Su, G. (2003). Activation of PPAR�?� is required for upregulation of CYP4A in hepatic steatosis induced by orotic acid. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Conference. World Scientific Publishing.
  • Liu, L., Markus, I., Vandenberg, R., Murray, M., Burcher, E. (2003). Distribution, expression and functional activity of three tachykinin NK1 receptor isoforms from Bufo Marinus. Society for Neuroscience, Washington DC: Society for Neuroscience.
  • Marden, N., Murray, M. (2003). Regulation of human cytochrome P450 2J2 by small Maf proteins and Nrf3. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Conference. World Scientific Publishing.
  • Liu, L., Markus, I., Neilan, B., Murray, M., Burcher, E. (2002). Cloning of bufokinin (tachykinin) receptors from the toad brain. Australian Neuroscience Society 23rd Annual Meeting, Burlington, MA: Academic Press Elsevier.
  • Liu, L., Markus, I., Murray, M., Neilan, B., Burcher, E. (2002). Multiple isoforms of tachykinin NK1 receptor in toad gut and brain. Proceedings of the Australian Health and Medical Research Congress 2002, : British Medical Journal Publishing Group.
  • Anggono, V., Marden, N., Murray, M. (2002). Nitric Oxide down regulates cytochrome P450 2J2 via mitogen-activated protein kinase pathways. Proceedings of the Australian Health and Medical Research Congress 2002, : British Medical Journal Publishing Group.
  • Su, G., Fiala-Beer, E., Murray, M. (2002). Regulation of SOCS genes in vitamin A deficient rat liver. Proceedings of the Australian Health and Medical Research Congress 2002, : British Medical Journal Publishing Group.
  • Marden, N., XIANG, S., Murray, M. (2002). Role of AP-1 in the regulation of human cytochrome P450 2J2 in hypoxia. Proceedings of the Australian Health and Medical Research Congress 2002, : British Medical Journal Publishing Group.
  • Murray, M. (2002). Toxicology. British Toxicological Society meeting, Ireland: Elsevier.
  • Murray, M., Marden, N., Anggono, V., XIANG, S., Fiala-Beer, E. (2002). Transcriptional regulation of endobiotic oxidising cytochromes P450. Proceedings of the Australian Health and Medical Research Congress 2002, : British Medical Journal Publishing Group.
  • Murray, M., Fiala-Beer, E., Sefton, R., Su, G. (2002). Upregulation of CYPs 4A in microsomal and plasma membrane fractions from rats with orotic acid-induced steatosis. Proceedings of the Australian Health and Medical Research Congress 2002, : British Medical Journal Publishing Group.
  • Su, G., Fiala-Beer, E., Murray, M. (2001). Dysregulation of the tyrosine phosphatase SHP-1 in Vitamin A-deficient rat liver. Australian Society for Medical Research Meeting, Sydney, NSW, Australia: The Australian Society for Medical Research.

2014

  • Toh, D., Limenta, L., Yee, J., Wang, L., Goh, B., Murray, M., Lee, E. (2014). Effect of mushroom diet on pharmacokinetics of gabapentin in healthy Chinese subjects. British Journal of Clinical Pharmacology, 78(1), 129-134. [More Information]
  • Murray, M., Dyari, H., Allison, S., Rawling, T. (2014). Lipid analogues as potential drugs for the regulation of mitochondrial cell death. British Journal of Pharmacology, 171(8), 2051-2066. [More Information]
  • Murray, M. (2014). ω-3 polyunsaturated fatty acids and their metabolites as inhibitors of mammalian tumorigenesis. Phytochemistry Reviews, 13(1), 139-156. [More Information]

2013

  • Cui, P., Rawling, T., Gillani, T., Bourget, K., Wang, X., Zhou, F., Murray, M. (2013). Anti-proliferative actions of N'-desmethylsorafenib in human breast cancer cells. Biochemical Pharmacology, 86(3), 419-427. [More Information]
  • Zhou, F., Zheng, J., Zhu, L., Jodal, A., Cui, P., Wong, K., Gurney, H., Church, W., Murray, M. (2013). Functional Analysis of Novel Polymorphisms in the Human SLCO1A2 Gene that Encodes the Transporter OATP1A2. The AAPS Journal, 15(4), 1099-1108. [More Information]
  • Toh, D., Cheung, F., Murray, M., Pern, T., Lee, E., Zhou, F. (2013). Functional Analysis of Novel Variants in the Organic Cation/Ergothioneine Transporter 1 Identified in Singapore Populations. Molecular Pharmaceutics, 10(7), 2509-2516. [More Information]
  • Ghassabian, S., Murray, M. (2013). Simultaneous In Vivo Phenotyping of CYP Enzymes. In Phillips, Ian R.; Shephard, Elizabeth A.; Ortiz de Montellano, Paul R (Eds.), Cytochrome P450 Protocols, (pp. 261-267). New York: Springer.

2012

  • Cui, P., Rawling, T., Bourget, K., Kim, T., Duke, C., Doddareddy, M., Hibbs, D., Zhou, F., Tattam, B., Petrovic, N., Murray, M. (2012). Antiproliferative and Antimigratory Actions of Synthetic Long Chain n-3 Monounsaturated Fatty Acids in Breast Cancer Cells That Overexpress Cyclooxygenase-2. Journal of Medicinal Chemistry, 55(16), 7163-7172. [More Information]
  • Armour, C., Chaar, B., Murray, M., Ambler, G., Krass, I. (2012). Current therapies and pharmacy programs for obesity and diabetes. In Louise A. Baur, Stephen M. Twigg, Roger S.Magnusson (Eds.), A Modern Epidemic: Expert Perspectives on Obesity and Diabetes, (pp. 315-338). Sydney, Australia: Sydney University Press.
  • Murray, M. (2012). Introduction and Overview. In Pavel Anzenbacher and Ulrich M Zanger (Eds.), Metabolism of Drugs and Other Xenobiotics, (pp. 519-542). Weinheim: Wiley - V C H Verlag GmbH & Co. KGaA.
  • Ghassabian, S., Rawling, T., Zhou, F., Doddareddy, M., Tattam, B., Hibbs, D., Edwards, R., Cui, P., Murray, M. (2012). Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites. Biochemical Pharmacology, 84(2), 215-223. [More Information]
  • Rawling, T., McDonagh, A., Tattam, B., Murray, M. (2012). Synthesis of unsymmetrical biaryl ureas from N-carbamoylimidazoles: kinetics and application. Tetrahedron, 68(30), 6065-6070. [More Information]
  • Murray, M. (2012). Toxicological actions of plant-derived and anthropogenic methylenedioxyphenyl-substituted chemicals in mammals and insects. Journal of Toxicology and Environmental Health. Part B: Critical Reviews, 15(6), 365-395. [More Information]

2011

  • Toh, S., Murray, M., Tan, K., Mulay, V., Grewal, T., Lee, E., Zhou, F. (2011). Functional analysis of pharmacogenetic variants of human organic cation/carnitine transporter 2 (hOCTN2) identified in Singaporean populations. Biochemical Pharmacology, 82(11), 1692-1699. [More Information]
  • Zhou, F., Lee, A., Krafczyk, K., Zhu, L., Murray, M. (2011). Protein Kinase C Regulates the Internalization and Function of the Human Organic Anion Transporting Polypeptide 1A2. British Journal of Pharmacology, 162(6), 1380-1388. [More Information]
  • Cui, P., Petrovic, N., Murray, M. (2011). The ω-3 Epoxide of Eicosapentaenoic Acid Inhibits Endothelial Cell Proliferation by p38 MAP Kinase Activation and Cyclin D1/CDK4 Down-Regulation. British Journal of Pharmacology, 162(5), 1143-1155. [More Information]

2010

  • Rong, X., Li, Y., Ebihara, K., Zhao, M., Naowaboot, J., Kusakabe, T., Kuwahara, K., Murray, M., Nakao, K. (2010). Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice. Diabetologia: clinical and experimental diabetes and metabolism, 53, 1727-1731. [More Information]
  • Murray, M. (2010). Cytochromes P450: Roles in the Biotransformation of Chemicals in Cigarette Smoke and Impact of Smoking Cessation on Concurrent Drug Therapy. Journal of Smoking Cessation, 5(2), 107-114. [More Information]
  • Rawling, T., Duke, C., Cui, P., Murray, M. (2010). Facile and Stereoselective Synthesis of (Z)-15-Octadecenoic Acid and (Z)-16-Nonadecenoic Acid: Monounsaturated Omega-3 Fatty Acids. Lipids, 45(2), 159-165. [More Information]
  • Zhou, F., Zhu, L., Cui, P., Church, W., Murray, M. (2010). Functional characterization of nonsynonymous single nucleotide polymorphisms in the human organic anion transporter 4 (hOAT4). British Journal of Pharmacology, 159, 419-427. [More Information]
  • Toh, S., Yee, J., Koo, S., Murray, M., Lee, E. (2010). Genetic Variations of the SLC22A5 Gene in the Chinese and Indian Populations of Singapore. Drug Metabolism and Pharmacokinetics, 25(1), 112-119. [More Information]
  • D'Esposito, F., Nebot, N., Edwards, R., Murray, M. (2010). Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease. British Journal of Clinical Pharmacology, 70(3), 400-408. [More Information]
  • Cui, P., Lee, A., Zhou, F., Murray, M. (2010). Impaired transactivation of the human CYP2J2 arachidonic acid epoxygenase gene in HepG2 cells subjected to nitrative stress. British Journal of Pharmacology, 159(7), 1440-1449. [More Information]
  • Rong, X., Li, Y., Ebihara, K., Zhao, M., Kusakabe, T., Tomita, T., Murray, M., Nakao, K. (2010). Irbesartan treatment up-regulates hepatic expression of PPARalpha and its target genes in obese Koletsky (fa(k)/fa(k)) rats: a link to amelioration of hypertriglyceridaemia. British Journal of Pharmacology, 160(7), 1796-1807. [More Information]
  • Nebot, N., Crettol, S., D'Esposito, F., Tattam, B., Hibbs, D., Murray, M. (2010). Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. British Journal of Pharmacology, 161(5), 1059-1069. [More Information]
  • Crettol, S., Petrovic, N., Murray, M. (2010). Pharmacogenetics of phase I and phase II drug metabolism. Current Pharmaceutical Design, 16(2), 204-219. [More Information]
  • Murray, M., Cui, P., Zhou, F. (2010). Roles of Mitogen-Activated Protein Kinases in the Regulation of CYP Genes. Current Drug Metabolism, 11(10), 850-858. [More Information]
  • Ghassabian, S., Chetty, M., Tattam, B., Glen, J., Rahme, J., Stankovic, Z., Ramzan, I., Murray, M., McLachlan, A. (2010). The participation of cytochrome P450 3A4 in clozapine biotransformation is detected in people with schizophrenia by high-throughput in vivo phenotyping. Journal of Clinical Psychopharmacology, 30(5), 629-631. [More Information]
  • Lee, A., Murray, M. (2010). Up-Regulation of Human CYP2J2 in HepG2 Cells by Butylated Hydroxyanisole Is Mediated by c-Jun and Nrf2. Molecular Pharmacology, 77(6), 987-994. [More Information]
  • Petrovic, N., Murray, M. (2010). Using N,N,N',N'-tetramethyl-p-phenylenediamine (TMPD) to assay cyclooxygenase activity in vitro. In Donald Armstrong (Eds.), Methods in Molecular Biology: Advanced Protocols in Oxidative Stress II, (pp. 129-140). New York USA: Humana Press.
  • Li, Y., Saito, Y., Kuwahara, K., Rong, X., Kishimoto, I., Harada, M., Horiuchi, M., Murray, M., Nakao, K. (2010). Vasodilator therapy with hydralazine induces angiotensin AT2 receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A. British Journal of Pharmacology, 159, 1133-1142. [More Information]

2009

  • Ghassabian, S., Chetty, M., Tattam, B., Glen, J., Rahme, J., Stankovic, Z., Ramzan, I., Murray, M., McLachlan, A. (2009). A high-throughput assay using liquid chromatography-tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome p450 enzymes in patients. Therapeutic Drug Monitoring, 31(2), 239-246. [More Information]
  • Rong, X., Li, Y., Ebihara, K., Zhao, M., Aini, W., Kusakabe, T., Hirata, M., Miyamoto, L., Murray, M., Nakao, K. (2009). An Adipose Tissue-Independent Insulin-Sensitizing Action of Telmisartan: a Study in Lipodystrophic Mice. Journal of Pharmacology and Experimental Therapeutics, 331(3), 1096-1103. [More Information]
  • Toh, S., Koo, S., Limenta, L., Yee, J., Murray, M., Lee, E. (2009). Genetic Variations of the SLC22A4 Gene in Chinese and Indian Populations of Singapore. Drug Metabolism and Pharmacokinetics, 24(5), 475-481.
  • Li, Y., Saito, Y., Kuwahara, K., Rong, X., Kishimoto, I., Harada, M., Adachi, Y., Nakanishi, M., Kinoshita, H., Horiuchi, M., Murray, M., et al (2009). Guanylyl Cyclase-A Inhibits Angiotensin II Type 2 Receptor-Mediated Pro-Hypertrophic Signaling in the Heart. Endocrinology, 150(8), 3759-3765. [More Information]
  • Chetty, M., D'Esposito, F., Zhang, W., Glen, J., Dore, G., Stankovic, Z., Edwards, R., Ramzan, I., Murray, M. (2009). In vitro and in vivo evaluation of the inhibition potential of risperidone toward clozapine biotransformation. British Journal of Clinical Pharmacology, 68(4), 574-579. [More Information]
  • Xu, H., Murray, M., McLachlan, A. (2009). Influence of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Sulfonylurea Drugs. Current Drug Metabolism, 10(6), 643-658. [More Information]
  • Cui, P., Zhang, W., Hook, J., Tattam, B., Duke, C., Murray, M. (2009). Synthesis and NMR characterization of the methyl esters of eicosapentaenoic acid monoepoxides. Chemistry and Physics of Lipids, 159(1), 30-37. [More Information]
  • Millar, A., Qi, Y., Rong, X., Jiang, J., Yang, Q., Yamahara, J., Murray, M., Li, Y. (2009). The Ayurvedic medicine Salacia oblonga attenuates diabetic renal fibrosis in rats: suppression of angiotensin II/AT1 signaling. Evidence-Based Complementary and Alternative Medicine, , 1 of 13-13 of 13. [More Information]

2008

  • D'Esposito, F., Tattam, B., Ramzan, I., Murray, M. (2008). A liquid chromatography/electrospray ionization mass spectrometry (LC-MS/MS) assay for the determination of irinotecan (CPT-11) and its two major metabolites in human liver microsomal incubations and human plasma samples. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 875(2), 522-530. [More Information]
  • Rong, X., Kim, M., Su, N., Wen, S., Matsuo, Y., Yamahara, J., Murray, M., Li, Y. (2008). An aqueous extract of Salacia oblonga root, a herb-derived peroxisome proliferator-activated receptor-alpha activator, by oral gavage over 28 days induces gender-dependent hepatic hypertrophy in rats. Food and Chemical Toxicology, 46(6), 2165-2172. [More Information]
  • Xu, H., Williams, K., Liauw, W., Murray, M., Day, R., McLachlan, A. (2008). Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. British Journal of Pharmacology, 153(7), 1579-1586. [More Information]
  • Li, Y., Qi, Y., Kim, M., Zhe-Yang Xu, K., Huang, H., Rong, X., Murray, M., Yamahara, J. (2008). Increased renal collagen cross-linking and lipid accumulation in nephropathy of Zucker diabetic fatty rats. Diabetes - Metabolism: Research and Reviews, 24(6), 498-506. [More Information]
  • Zhang, W., D'Esposito, F., Edwards, R., Ramzan, I., Murray, M. (2008). Interindividual Variation in Relative CYP1A2/3A4 Phenotype Influences Susceptibility of Clozapine Oxidation to Cytochrome P450-Specific Inhibition in Human Hepatic Microsomes. Drug Metabolism and Disposition, 36(12), 2547-2555. [More Information]
  • Szymczak, M., Murray, M., Petrovic, N. (2008). Modulation of angiogenesis by omega-3 polyunsaturated fatty acids is mediated by cyclooxygenases. Blood, 111(7), 3514-3521. [More Information]
  • Murray, M. (2008). Modulation of Cytochromes P450 by Phytochemicals. In Costas Ioannides (Eds.), Cytochromes P450: Role in the Metabolism and Toxicity of Drugs and other Xenobiotics, (pp. 449-479). UK: RSC Publishing.
  • Petrovic, N., Murray, M. (2008). Modulation of Tumor Angiogenesis by Polyunsaturated Fatty Acids: What is the Mechanism? In Peter B. Murphy and Jason R. Clarke (Eds.), Oncogene Proteins: Structure, Functions and Analyses, (pp. 117-138). USA: Nova Science Publishers.

2007

  • Shankar, G., Charleston, M., Murray, M., Hibbs, D. (2007). A structural and phylogenetic analysis of cytochrome P450. In Damjana Rozman (Eds.), Proceedings of the 15th International Conference on Cytochromes P450: Biochemistry, Biophysics and Functional Genomics, (pp. 75-80). Bologna, Italy: Medimond.
  • Chetty, M., Murray, M. (2007). CYP-mediated clozapine interactions: how predictable are they? Current Drug Metabolism, 8(4), 307-313. [More Information]
  • Zhang, W., Ramzan, I., Murray, M. (2007). Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis. Journal of Pharmacology and Experimental Therapeutics, 322(2), 770-777. [More Information]
  • Fiala-Beer, E., Lee, A., Murray, M. (2007). Regulation of the rat CYP4A2 gene promoter by c-Jun and octamer binding protein-1. The International Journal of Biochemistry and Cell Biology, 39(6), 1235-1247. [More Information]
  • Murray, M. (2007). Role of signalling systems in the effects of dietary factors on the expression of mammalian CYPs. Expert Opinion on Drug Metabolism and Toxicology, 3(2), 185-196. [More Information]

2006

  • Murray, M., Zhang, W., Duke, C., Ramzan, I. (2006). Accumulation of esterified polyunsaturated fatty acids in hepatic steatosis impairs microsomal clozapine oxidation. Australian Health and Medical Research Congress, Melbourne: Australian Health and Medical Research Congress.
  • Murray, M., Marden, N., Lee, A. (2006). Altered CYP expression and function by dietary factors: Potential roles in disease pathogenesis. 14th North American ISSX (International Society for the Study of Xenobiotics) Meeting, United States: Informa Healthcare.
  • Murray, M. (2006). Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis. Current Drug Metabolism, 7(1), 67-81. [More Information]
  • Murray, M., Petrovic, N. (2006). Cytochromes P450: Decision-making tools for personalized therapeutics. Current Opinion in Molecular Therapeutics, 8(6), 480-486. [More Information]
  • D'Esposito, F., Tattam, B., Ramzan, I., Murray, M. (2006). Development of a high throughput LC/MS/MS method for the determination of the anticancer agent irinotecan and its two major metabolites. Australian Health and Medical Research Congress, Melbourne: Australian Health and Medical Research Congress.
  • Obligacion, R., Murray, M., Ramzan, I. (2006). Drug-Metabolizing Enzymes and Review Transporters: Expression in the Human Prostate and Roles in Prostate Drug Disposition. Journal Of Andrology, 27(2), 138-150. [More Information]
  • Cowpland, C., Quee, G., Murray, M., Puddey, I., Croft, K. (2006). Effect of alcohol on cytochrome P450 arachidonic acid metabolism and blood pressure in rats and its modulation by red wine polyphenolics. Clinical and Experimental Pharmacology and Physiology, 33(3), 183-188. [More Information]
  • Murray, M., Zhang, W., Ramzan, I. (2006). Hepatic lipid accumulation in experimental steatosis influences microsomal clozapine oxidation capacity.
  • Murray, M., Zhang, W., Ramzan, I. (2006). Hepatic lipid accumulation in experimental steatosis influences microsomal clozapine oxidation capacity. 14th North American ISSX (International Society for the Study of Xenobiotics) Meeting, United States: Informa Healthcare.
  • Shankar, G., Charleston, M., Murray, M., Hibbs, D. (2006). Phylogenetic analysis of cytochrome P450 structures. BIOINFORMATICS AUSTRALIA 2006, Sydney: NSW Office for Science and Medical Research.
  • Murray, M. (2006). Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. Journal of Pharmacy and Pharmacology, 58(7), 871-885. [More Information]

2005

  • Marden, N., Murray, M. (2005). Characterization of a c-Jun-responsive module in the 5'-flank of the human CYP2J2 gene that regulates transactivation. Biochemical Journal, 391(3), 631-640. [More Information]
  • Murray, M., Butler, A., Fiala-Beer, E., Su, G. (2005). Phospho-STAT5 accumulation in nuclear fractions from vitamin A-deficient rat liver. FEBS Letters, 579(17), 3669-3673. [More Information]
  • Lee, A., Marden, N., Murray, M. (2005). Potential transcriptional control elements in the 5'-upstream region of the human CYP2J2 gene. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Conference. World Scientific Publishing.
  • Su, G., Fiala-Beer, E., Weber, J., Jahn, D., Robertson, G., Murray, M. (2005). Pretranslational upregulation of microsomal CYP4A in rat liver by intake of a high-sucrose, lipid-devoid diet containing orotic acid. Biochemical Pharmacology, 69(4), 709-717. [More Information]
  • Liu, L., Murray, M., Conlon, J., Burcher, E. (2005). Quantitative Structure-Activity analyses of bufokinin and other tachykinins at bufokinin (bNK1) receptors of the small intestine of the can toad, Bufo marinus. Biochemical Pharmacology, 69(2), 329-338. [More Information]
  • Murray, M., Fiala-Beer, E. (2005). Role of c-Jun in the transcriptional activation of the rat cytochrome P450 (CYP) 4A2. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Conference. World Scientific Publishing.
  • Ghassabian, S., Murray, M., Chetty, M., Glen, J. (2005). The impact of Valproate on Plasma Concentrations of Clozapine nad Its Major Metabolites in Patients with Schizophrenia. Joint Meeting of Ascept and Apsa, Melbourne: Australian Society of Clinical and experimental Pharmacologists and Toxicologista.

2004

  • Marden, N., Murray, M. (2004). Characterisation of a c-jun-responsive module in the 5'-flank of the human CYP2J2 gene that regulates expression. Australian Health and Medical Research Congress, Melbourne: Australian Health and Medical Research Congress.
  • Murray, M., Butler, A. (2004). Comparative Inhibition Of Inducible And Constitutive Cyps In Rat Hepatic Microsomes By Parathion. Xenobiotica, 34(8), 723-739.
  • Liu, L., Markus, I., Vandenberg, R., Neilan, B., Murray, M., Burcher, E. (2004). Molecular Identification And Characterization Of Three Isoforms Of Tachykinin Nk(1)-Like Receptors In The Cane Toad Bufo Marinus. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology (Print), 287(3), R575-R585.

2003

  • Murray, M., Fiala-Beer, E., Weber, J., Robertson, C., Farrell, G., Su, G. (2003). Activation of PPAR�?� is required for upregulation of CYP4A in hepatic steatosis induced by orotic acid. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Conference. World Scientific Publishing.
  • Liu, L., Markus, I., Vandenberg, R., Murray, M., Burcher, E. (2003). Distribution, expression and functional activity of three tachykinin NK1 receptor isoforms from Bufo Marinus. Society for Neuroscience, Washington DC: Society for Neuroscience.
  • Murray, M., Murray, K. (2003). Mechanism-based inhibition of CYP activities in rat liver by fluoxetine and structurally similar alkylamines. Xenobiotica, 33(10), 973-987.
  • Murray, M. (2003). Pharmacogenetic variation in drug oxidizing CYPs: impact on drug therapy, drug safety and drug interactions. Current Pharmacogenomics and Personalized Medicine, 1(3), 159-173.
  • Marden, N., Murray, M. (2003). Regulation of human cytochrome P450 2J2 by small Maf proteins and Nrf3. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Conference. World Scientific Publishing.
  • Marden, N., Fiala-Beer, E., XIANG, S., Murray, M. (2003). Role of activator protein-1 in the down-regulation of the human CYP2J2 gene in hypoxia. Biochemical Journal, 373(3), 669-680.
  • Murray, M., Fiala-Beer, E., Sutton, D. (2003). Upregulation of cytochromes P450 2B in rat liver by orphenadrine. British Journal of Pharmacology, 139(4), 787-796.

2002

  • Liu, L., Markus, I., Neilan, B., Murray, M., Burcher, E. (2002). Cloning of bufokinin (tachykinin) receptors from the toad brain. Australian Neuroscience Society 23rd Annual Meeting, Burlington, MA: Academic Press Elsevier.
  • Stupans, I., Tan, H., Kirlich, A., Tuck, K., Hayball, P., Murray, M. (2002). Inhibition of CYP3A-mediated oxidation in human hepatic microsomes by the dietary derived complex phenol, gallic acid. Journal of Pharmacy and Pharmacology, 54, 269-275.
  • Liu, L., Markus, I., Murray, M., Neilan, B., Burcher, E. (2002). Multiple isoforms of tachykinin NK1 receptor in toad gut and brain. Proceedings of the Australian Health and Medical Research Congress 2002, : British Medical Journal Publishing Group.
  • Anggono, V., Marden, N., Murray, M. (2002). Nitric Oxide down regulates cytochrome P450 2J2 via mitogen-activated protein kinase pathways. Proceedings of the Australian Health and Medical Research Congress 2002, : British Medical Journal Publishing Group.
  • Su, G., Fiala-Beer, E., Murray, M. (2002). Regulation of SOCS genes in vitamin A deficient rat liver. Proceedings of the Australian Health and Medical Research Congress 2002, : British Medical Journal Publishing Group.
  • Marden, N., XIANG, S., Murray, M. (2002). Role of AP-1 in the regulation of human cytochrome P450 2J2 in hypoxia. Proceedings of the Australian Health and Medical Research Congress 2002, : British Medical Journal Publishing Group.
  • Liu, L., Murray, M., Burcher, E. (2002). Structure-activity studies of bufokinin, substance P and their C-terminal fragments at bufokinin receptors in the small intestine of the cane toad, Bufo marinus. Biochemical Pharmacology, 63(2), 217-224.
  • Murray, M. (2002). Toxicology. British Toxicological Society meeting, Ireland: Elsevier.
  • Murray, M., Marden, N., Anggono, V., XIANG, S., Fiala-Beer, E. (2002). Transcriptional regulation of endobiotic oxidising cytochromes P450. Proceedings of the Australian Health and Medical Research Congress 2002, : British Medical Journal Publishing Group.
  • Murray, M., Fiala-Beer, E., Sefton, R., Su, G. (2002). Upregulation of CYPs 4A in microsomal and plasma membrane fractions from rats with orotic acid-induced steatosis. Proceedings of the Australian Health and Medical Research Congress 2002, : British Medical Journal Publishing Group.

2001

  • Hoskins, J., Shenfield, G., Murray, M., Gross, A. (2001). Characterization of moclobemide N-oxidation in human liver microsomes. Xenobiotica, 31(7), 387-397.
  • Murray, M., Sefton, R., Croft, K., Butler, A. (2001). Differential regulation of endobiotic-oxidizing cytochromes P450 in vitamin A-deficient male rat liver. British Journal of Pharmacology, 134(7), 1487-1497.
  • Su, G., Fiala-Beer, E., Murray, M. (2001). Dysregulation of the tyrosine phosphatase SHP-1 in Vitamin A-deficient rat liver. Australian Society for Medical Research Meeting, Sydney, NSW, Australia: The Australian Society for Medical Research.
  • Stupans, I., Murray, M., Kirlich, A., Tuck, K., Hayball, P. (2001). Inactivation of cytochrome P450 by the food-derived complex phenol oleuropein. Food and Chemical Toxicology, 39, 1119-1124.

To update your profile click here. For support on your academic profile contact .